Home / Health / ADA: Novo Nordisk's oral semaglutid submits a different heart safety gain

ADA: Novo Nordisk's oral semaglutid submits a different heart safety gain



SAN FRANCISCO-Novo Nordisk may have already submitted its application for approval for its oral drug for oral GLP-1, but the positive data has not ceased.

Tuesday at the American Diabetes Association annual meeting, the Danish drugmaker rolled out cardiovascular results showing that its wannabe blockbuster did not damage cardiovascular safety in high-risk type 2 diabetes patients.

RELATED: Novo Nordisk stokes GLP-1 hopes that weekly semaglutid lowers heart risk by 26%

Free Daily Newsletter

Do you like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where great ideas come together daily. Our subscribers trust FiercePharma as their most read source for the latest news, analysis and drug data and the companies that make them. Register today to get pharma news and updates delivered to your inbox and read on the go.

The study did not aim to show that the drug could give the heart benefits, as others in semaglutid's GLP-1

class have. And that's because Novo already has data showing that an injectable version of the compound – already on the market as Ozempic – could reduce the combined risk of heart attack, stroke and cardiovascular death by 26%.

"When it enters the bloodstream, it's the same molecule," Todd Hobbs, Novo's American chief physician, pointed out, and the company hopes to ultimately have both sets of data on oral semaglutide label. "Overall, we really hope it is beneficial," he says.

Earlier in the meeting, semaglutid continued its trouncing of already marketed diabetes products and sent more data from head to head – this time from the one-year brand to both SGLT2 market leader Jardiance from Eli Lilly and Boehringer Ingelheim and Novo's own older generation GLP-1 , Victoza.

In a study called Pioneer 2, the candidate was still significantly topped in Jardiance by reducing A1C, a common blood glucose action, at 52 weeks. And in Pioneer 4, it achieved the same performance against both Victoza and placebo in a year's time, leading to a 1.2% decrease against the older drug's .9% and placebo .2% rating.

"When you look at all the Pioneer studies on the treatment cascade from the beginning to even adding to insulin, it is really a good message to see that it is superior and has a very nice profile through all these studies, Hobbs.

With such results, Novo hopes to see some movement from primary care personnel who have not yet jumped on the GLP-1 carriage. Right now, they are "really not cared for GLP-1 perhaps as they should with the guidelines that support their use," "Hobbs said." What we hope are the primary care physicians, especially those who are not familiar with using injectable GLP-1s "will" embrace GLP-1 orally. "

RELATED: Novo has a big price decision to make How fast oral semaglutide may be assumed once depends on Novo's pricing, which for many years has been a subject of much speculation, and while Hobbs said that COMPANY has not set their price, are already "doing everything we can" to work with payers in the meantime.

"We definitely want to make it competitive," Hobbs said, noting that the drug's price will not necessarily be considered a small molecular price. "

" We definitely want to make sure that access is not an obstacle, "he added.


Source link